Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Silo Pharma ( (SILO) ) has shared an announcement.
On May 16, 2025, Silo Pharma completed a public offering of shares and warrants, raising approximately $1.56 million in net proceeds. The company plans to use the funds for working capital and general corporate purposes, which may impact its operations and market positioning by providing financial resources for its developmental projects.
More about Silo Pharma
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
Average Trading Volume: 254,004
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.75M
Learn more about SILO stock on TipRanks’ Stock Analysis page.